Navigation Links
NeurogesX Reports Third Quarter 2008 Results
Date:11/6/2008

e potential utility of such partnerships in connection with NeurogesX' non-NGX-4010 development efforts; the potential markets for NeurogesX' product candidates; expected benefits of NeurogesX' product candidates; and the suitability of NGX-1998 for certain treatments and potential usage by broader physician populations. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; any regulatory approvals which are received may be limited to certain indications; maintaining or obtaining adequate cash and other resources to carry on operations through potential regulatory approval of NGX-4010 and to carry out activities to commercialize NGX-4010, if approved; difficulties or delays in NeurogesX entering into commercialization partnerships for NGX-4010; physician or patient reluctance to use NGX-4010 or NGX-1998, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; other difficulties or delays in, clinical development, obtaining regulatory approval, market acceptance and commercialization of NeurogesX' product candidates and the advantages of NeurogesX' product candidates over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

NeurogesX, Inc.

(A Development Stage Company)

Condensed Consolidated Statements of Operations

'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. NeurogesX Appoints New Director to the Board
3. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
4. NeurogesX Expands Senior Management Team
5. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
7. NeurogesX, Inc. Announces $25 Million Private Placement
8. NeurogesX Closes $25 Million Private Placement
9. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
10. NeurogesX to Present at Roth 2008 OC Growth Stock Conference
11. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Oro Valley, Arizona (PRWEB) September 16, 2014 ... company that develops safe and effective products to ... through the use of a proprietary SPACEā„¢ Technology ... Executive Officer and President will present at the ... 18, 2014 at the Hyatt Regency Phoenix. ...
(Date:9/16/2014)... 2014  Ascendis Pharma A/S, a biotechnology company ... significant unmet medical needs, today announced positive interim ... to evaluate once-weekly TransCon Growth Hormone in children ... interim results will be presented at the 7th ... being held October 15-18, 2014, in Singapore.  ...
(Date:9/16/2014)... Canada (PRWEB) September 16, 2014 According ... the Toronto affiliate of ITRA Global, new development in ... the Toronto city council approving another 755 storeys of ... it appears construction cranes will be dominating the Toronto ... seems to have an unquenchable thirst for new development. ...
(Date:9/15/2014)... , Sept. 15, 2014   Global ... innovator of scientific products and services for satellite ... Acquisition Solution for Integrated Services (OASIS) from the ... GST was selected to provide the government best-value ... Small Business (SB) category in Pool 4. The ...
Breaking Biology Technology:Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 2Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 2Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 3
... results in physician,s office -, MADISON, N.J., ... Quest Diagnostics Incorporated (NYSE: DGX ),today announced ... T(TM) fecal,immunochemical test, a point-of-care version of the ... the sensitivity and,specificity of the laboratory-based InSure FIT ...
... Announces CE Mark Approval for First Product, the CorMatrix ... ECM(TM) for ... an,Atlanta- based company dedicated to developing and delivering unique,extracellular matrix ... damaged cardiovascular tissue, announced,today that the company has received 510(k) ...
... Pursues Strategy of Reducing Heart Attack Deaths by Shielding ... High-Risk Plaques ... Prescient Medical, Inc., a,privately held medical device company dedicated ... results on the chemical,characterization and treatment of rupture-prone or ...
Cached Biology Technology:Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening 2Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening 3Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening 4Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening 5CorMatrix(R) Announces FDA 510(k) for Novel Biomaterial Implant for Intracardiac Repair 2CorMatrix(R) Announces FDA 510(k) for Novel Biomaterial Implant for Intracardiac Repair 3CorMatrix(R) Announces FDA 510(k) for Novel Biomaterial Implant for Intracardiac Repair 4Prescient Medical, Inc. to Present Data on Identification and Treatment of Rupture-Prone Coronary Plaques at EuroPCR 2008 2
(Date:9/16/2014)... year, a new football season and another commercial cargo ... Dragon spacecraft is scheduled to blast off to the ... the company,s fourth contracted mission to the complex. , ... of research investigations sponsored by the Center for the ... of managing the U.S. National Laboratory on the space ...
(Date:9/16/2014)... A complex web of interaction between viruses, bacteria, ... by a growing international collaboration between Matthew Sullivan, ... of Ecology and Evolutionary Biology and Steven Hallam ... Canada. , "Bacteria are drivers of nutrient ... said. "As the climate is changing, so are ...
(Date:9/16/2014)... (KXL) would likely increase oil sands extraction, according to ... non-profit organization Near Zero. The results are detailed in ... both supporters and opponents of the pipeline. ... to significantly higher greenhouse gas emissions, with the exact ... "This report examines three main scenarios discussed by participants ...
Breaking Biology News(10 mins):CASIS research set for launch aboard SpaceX mission to space station 2CASIS research set for launch aboard SpaceX mission to space station 3New research decodes virus-host interactions in ocean dead zones 2New research decodes virus-host interactions in ocean dead zones 3Keystone XL would likely raise oil sands production and greenhouse gas emissions 2
... the University of California, Riverside are part of a ... living bacteria a discovery that could help in ... The research team believes this is the first ... biological rather than chemical means. It opens the door ...
... teaming up with colleagues in other higher education institutions ... courses. They include research into a mobile biosensor, ... sports, and a manufacturing process to make titanium golf ... seven collaborative studentships, currently underway in the East Midlands. ...
... a diesel engine is far from easy. Due to ... combustion cycles are the same. Furthermore, the measurements are ... is injected into the cylinder causes an extra source ... cylinder with an engine adapted for this purpose. ...
Cached Biology News:Nanotube-producing bacteria show manufacturing promise 2
... Plates are designed for quick and easy ... plates feature two 0.25mm holes laser cut ... The wells remain liquid-tight during incubation of ... time the protein diffuses from the gel ...
... is a direct antibiotic-based ... identification. Recombinant selection depends ... eliminating the need for ... quick and inexpensive process ...
... Enhancer does for enzyme-/substrate-based blotting what intensifying screens ... signal up to 10-fold (or one order of ... Blot Signal Enhancer membrane treatment is a simple, ... your current Western blotting protocol. The result is ...
... a multi-functional program that searches ... a sequence file for polymerase ... site-directed mutagenesis, and various hybridization ... and secondary structure of oligonucleotides ...
Biology Products: